The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia

Author： Pai A.B.   Smeeding J.E.   Brook R.A.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.20, Iss.7, 2004-07, pp. : 991-999

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

National Kidney Foundation K-DOQI: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease

By  

Clinical Review in Bone and Mineral Metabolism, Vol. 5, Iss. 1, 2007-03 ,pp. : 53-67

Humana Press, Inc

Access to resources Recommend Favorite

Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom

By Thompson Melissa  

Journal of Medical Economics, Vol. 16, Iss. 6, 2013-06 ,pp. : 744-755

Informa Healthcare

Access to resources Recommend Favorite

Sevelamer carbonate in the management of hyperphosphatemia

By Kooienga L   Moore R  

Therapy, Vol. 5, Iss. 4, 2008-07 ,pp. : 545-552

Future Medicine

Access to resources Recommend Favorite

Hyperphosphatemia and vascular calcification in chronic kidney disease

By Cozzolino Mario   Brancaccio Diego  

Therapy, Vol. 3, Iss. 6, 2006-11 ,pp. : 691-692

Future Medicine

Access to resources Recommend Favorite

‘Trifecta’ outcomes of robot‐assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis

By  

BJU INTERNATIONAL, Vol. 121, Iss. 1, 2018-01 ,pp. : 119-123

John Wiley & Sons Inc

Access to resources Recommend Favorite